COVID-19, SARS-CoV-2
Conditions
Keywords
SARS-CoV-2, COVID-19, Immunocompromised Patients, Pre-exposure Prophylaxis Against COVID-19, Evusheld
Brief summary
An AstraZeneca-sponsored observational, electronic healthcare record (EHR)-embedded retrospective cohort study to assess the real-world effectiveness of EVUSHELD against SARS-CoV-2 infection, COVID-19-related hospitalization, and other COVID-19 related outcomes in the total EVUSHELD eligible patient population in the Clalit Health Services in Israel.
Detailed description
This a Phase IV observational, secondary data study to assess the effectiveness of EVUSHELD in preventing COVID-19 infection and severe outcomes using the electronic medical records from the nationwide integrated health system. The study is designed as an AstraZeneca-sponsored observational, electronic healthcare record (EHR)-embedded retrospective cohort study to assess the real-world effectiveness of EVUSHELD against SARS-CoV-2 infection, COVID-19-related hospitalization, and other COVID-19 related outcomes in the total EVUSHELD eligible patient population in the Clalit Health Services in Israel.
Interventions
DRUGEVUSHELD
EVUSHELD (AZD 7442, Tixagévimab/Cilgavimab)
Sponsors
Clalit Health Services
AstraZeneca
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
Individuals who meet all criteria below will be included. The eligibility criteria aligns with the guidelines of the Israeli Ministry of Health Inclusion criteria: * Aged 12 years and older as of the date of receipt of EVUSHELD * No record of infection or SARS-CoV- hospitalization within last 90 days prior to the index date * Individuals who are moderate/severe immune compromised due to a medical condition or receipt of immunosuppressive medications or treatments and may mount an adequate immune response to COVID-19 vaccine: * Hypogammaglobinemia patients regularly treated with immunoglobulins * Patients treated with B-cell depleting therapy, including for example such anti-CD20 as rituximab, obinatuzumab, ofatumumab, veltuzumab, Y-ibritumomab tiuxetan or ocrelizumab, even without malignant disease, up to six months from treatment. * Patients that are treated with B-cell depleting therapy (i.e. anti CD20, rituximab, Y-ibritumomab tiuxetan, veltuzumab, ofatumumab, obinatuzumab, ocrelizumab), without a malignant disease * Bone marrow transplant (up to a year from the BMT) from outside donors, or with GVHD grades 3-4. * Bone marrow transplant (up to a 6 months after the BMT) from self * Patients after (CAR) T-cell therapy (chimeric antigen receptor T-cell therapy) up to 6 months from the treatment. * Lungs transplant recipients * Solid organ transplant recipients (who has any kind of transplant) or those who received ATG (anti thymocyte globulin) over the last 6 months * Patients with aggressive lymphoma. * Multiple Myeloma patients that have active disease, and on treatment at the time of study initiation. Individuals who meet the criterion below will be excluded: Per the current FDA EUA, individuals currently infected with SARS-CoV-2 are not eligible for EVUSHELD as PrEP. Therefore, in the main analysis, individuals who meet the following criteria will also be excluded.
Exclusion criteria
* With evidence of COVID 19 (i.e., a positive diagnostic test, or COVID-19 diagnosis code) in the period of 90 days before (pseudo) index date OR * With evidence of SARS-CoV-2 infection on the (pseudo) index date or anytime within the 6-day period immediately following this date (i.e., index date to index date+6)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Hospitalisation due to COVID-19 | up to 6 months | Any record of admission to hospital that was reported to the Israeli MOH as hospitalization due to SARS-CoV-2 |
| All-cause mortality | up to 6 months | All-cause deaths reported in the patient's record |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| COVID-19-related healthcare resource utilization (HCRU) | 6 months | Any record of COVID-19 hospitalisation, ICU admission, mechanical ventilation and prescriptions of therapies for COVID-19 |
| COVID-19-related healthcare resource utilization | 6 months | Any record of hospital admission including hospital lenght of stay, ICU, mechanical ventilation, prescription/dispensations of antiviral drugs used for COVID-19 drugs |
| Documented SARS-CoV-2 Infection, COVID-19 related mortality, Severe COVID-19 | 6 months and 12 months | SARS-CoV-2 diagnostic test (eg, PCR, nucleic acid amplification, antigen) OR medical encounter resulting in a diagnosis code for COVID-19b OR medical encounter resulting in a code for isolation due to COVID-19 |
| Adverse events (AEs) | 12 months | Any record of Adverse events up to 12 months following initiation of Evusheld |
| SAEs/AESIs | 6 months | Any record of Serious Adverse Events (SAEs) or Adverse Events of Special Interests (AESIs) up to 6 months following initiation of Evusheld |
| COVID-19 mortality | 6 months and 12 months | Any record indicating death due to COVID-19 or record of death certificate mentioning SARS-CoV-2 as cause of death. |
Countries
Israel
Outcome results
None listed